Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study
- PMID: 26811150
- PMCID: PMC4973858
- DOI: 10.7326/M15-0983
Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study
Abstract
Background: The fecal immunochemical test (FIT) is a common method for colorectal cancer (CRC) screening, yet its acceptability and performance over several rounds of annual testing are largely unknown.
Objective: To assess FIT performance characteristics over 4 rounds of annual screening.
Design: Retrospective cohort study.
Setting: Kaiser Permanente Northern and Southern California.
Patients: 323 349 health plan members aged 50 to 70 years on their FIT mailing date in 2007 or 2008 who completed the first round of FIT and were followed for up to 4 screening rounds.
Measurements: Screening participation, FIT positivity (≥20 µg of hemoglobin/g), positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.
Results: Of the patients invited for screening, 48.2% participated in round 1. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of round 1 participants crossed over to endoscopy over 4 screening rounds-7.0% due to a positive FIT result. The FIT positivity rate (5.0%) and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in round 1. Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within 1 year of testing, including 84.5% in round 1 and 73.4% to 78.0% in subsequent rounds.
Limitation: Screening detection, rather than long-term cancer prevention, was evaluated.
Conclusion: Annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening.
Primary funding source: National Institutes of Health.
Conflict of interest statement
Figures


Similar articles
-
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5. Gastroenterology. 2017. PMID: 28483499
-
Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.Gut. 2018 Dec;67(12):2124-2130. doi: 10.1136/gutjnl-2017-314753. Epub 2017 Nov 3. Gut. 2018. PMID: 29101260
-
Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.Ann Intern Med. 2018 Nov 6;169(9):602-609. doi: 10.7326/M18-0855. Epub 2018 Oct 2. Ann Intern Med. 2018. PMID: 30285055
-
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Gut. 2015. PMID: 26041750 Review.
-
Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.Gastrointest Endosc. 2020 Mar;91(3):684-697.e15. doi: 10.1016/j.gie.2019.11.035. Epub 2019 Nov 30. Gastrointest Endosc. 2020. PMID: 31790657
Cited by
-
Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.Cancer Prev Res (Phila). 2021 Sep;14(9):845-850. doi: 10.1158/1940-6207.CAPR-21-0075. Epub 2021 May 21. Cancer Prev Res (Phila). 2021. PMID: 34021023 Free PMC article.
-
The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.United European Gastroenterol J. 2019 Apr;7(3):424-448. doi: 10.1177/2050640619828185. Epub 2019 Feb 6. United European Gastroenterol J. 2019. PMID: 31019712 Free PMC article.
-
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing.Am Health Drug Benefits. 2019 Sep;12(5):256-262. Am Health Drug Benefits. 2019. PMID: 32015794 Free PMC article.
-
Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.Am J Gastroenterol. 2018 Dec;113(12):1836-1847. doi: 10.1038/s41395-018-0106-8. Epub 2018 Jun 15. Am J Gastroenterol. 2018. PMID: 29904156 Free PMC article.
-
Colorectal cancer screening: An updated review of the available options.World J Gastroenterol. 2017 Jul 28;23(28):5086-5096. doi: 10.3748/wjg.v23.i28.5086. World J Gastroenterol. 2017. PMID: 28811705 Free PMC article. Review.
References
-
- Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73. doi: 10.1002/cncr.24760. - DOI - PMC - PubMed
-
- U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–37. - PubMed
-
- Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. American Cancer Society Colorectal Cancer Advisory Group Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–95. doi: 10.1053/j.gastro.2008.02.002. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical